Ani Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ANI PHARMS, and when can generic versions of ANI PHARMS drugs launch?
ANI PHARMS has two hundred and forty-two approved drugs.
There are two US patents protecting ANI PHARMS drugs. There is one tentative approval on ANI PHARMS drugs.
There are twenty-nine patent family members on ANI PHARMS drugs in twenty countries and one hundred and seventy supplementary protection certificates in sixteen countries.
Summary for Ani Pharms
| International Patents: | 29 |
| US Patents: | 2 |
| Tradenames: | 153 |
| Ingredients: | 146 |
| NDAs: | 242 |
Drugs and US Patents for Ani Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | CHLORPROPAMIDE | chlorpropamide | TABLET;ORAL | 088812-001 | Oct 19, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ani Pharms | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075432-002 | Oct 18, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ani Pharms | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; triamterene | CAPSULE;ORAL | 074259-001 | Mar 30, 1995 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ani Pharms | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 090861-001 | Mar 4, 2014 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ani Pharms | ETODOLAC | etodolac | CAPSULE;ORAL | 074844-002 | Dec 23, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ani Pharms | PURIFIED CORTROPHIN GEL | corticotropin | INJECTABLE;INJECTION | 008975-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ani Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ani Pharms | ATACAND | candesartan cilexetil | TABLET;ORAL | 020838-002 | Jun 4, 1998 | 5,534,534*PED | ⤷ Try a Trial |
| Ani Pharms | ATACAND HCT | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 021093-003 | May 16, 2008 | 5,958,961 | ⤷ Try a Trial |
| Ani Pharms | ATACAND HCT | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 021093-003 | May 16, 2008 | 5,196,444*PED | ⤷ Try a Trial |
| Ani Pharms | ATACAND | candesartan cilexetil | TABLET;ORAL | 020838-004 | Jun 4, 1998 | 5,508,297 | ⤷ Try a Trial |
| Ani Pharms | PANDEL | hydrocortisone probutate | CREAM;TOPICAL | 020453-001 | Feb 28, 1997 | 4,794,106 | ⤷ Try a Trial |
| Ani Pharms | ATACAND HCT | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 021093-002 | Sep 5, 2000 | 5,196,444*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ANI PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 16 mg/12.5 mg and 32 mg/12.5 mg | ➤ Subscribe | 2008-06-25 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg, 16 mg and 32 mg | ➤ Subscribe | 2006-12-22 |
| ➤ Subscribe | Tablets | 32 mg/25 mg | ➤ Subscribe | 2009-03-06 |
International Patents for Ani Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2005514358 | ⤷ Try a Trial |
| Denmark | 1448186 | ⤷ Try a Trial |
| China | 1323660 | ⤷ Try a Trial |
| Canada | 2466720 | ⤷ Try a Trial |
| Brazil | 0214256 | ⤷ Try a Trial |
| Hong Kong | 1131048 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ani Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0306228 | SPC/GB01/002 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 1874117 | 2014/032 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121 |
| 1109558 | 09C0001 | France | ⤷ Try a Trial | PRODUCT NAME: RANOLAZINE; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080714 |
| 1758590 | 2017C/063 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612 |
| 0720599 | 03C0028 | France | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
